公开(公告)号：US20180057603A1

公开(公告)日：2018-03-01

申请号：US15019924

申请日：2016-02-09

申请人： Mark Greene ,  Hongtao Zhang ,  Hiromichi Tsuchiya ,  Yasuhiro Nagai ,  Lian Lam ,  Aaron Runkle ,  Jeffrey Drebin ,  Mei Qing Ji

发明人： Mark Greene ,  Hongtao Zhang ,  Hiromichi Tsuchiya ,  Yasuhiro Nagai ,  Lian Lam ,  Aaron Runkle ,  Jeffrey Drebin ,  Mei Qing Ji

IPC分类号： C07K16/30 ,  A61K38/02 ,  A61K39/395

CPC分类号： C07K16/3076 ,  A61K31/337 ,  A61K31/517 ,  A61K38/02 ,  A61K38/217 ,  A61K39/395 ,  A61K39/39558 ,  A61K45/06 ,  A61K2039/505 ,  A61K2039/507 ,  A61K2039/545 ,  C07K16/2818 ,  C07K16/2863 ,  C07K16/32 ,  C07K2317/24 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/30 ,  C07K2319/70 ,  C07K2319/75 ,  A61K2300/00

摘要： The present invention provides a fusion proteins comprising (a) a first stretch of consecutive amino acids, the sequence of which is the sequence of an anti-p185her2/neu polypeptide or an anti-EGFR polypeptide; (b) a second stretch of consecutive amino acids, the sequence of which is the sequence of a polypeptide capable of binding at least one polypeptide other than p185her2/neu or EGFR; and (c) a third stretch of consecutive amino acids, the sequence of which comprises the sequence of a biologically active portion of interferon-gamma (IFNγ), wherein (b) is located at the carboxy-terminal end of (a), and (c) is located at the carboxy-terminal end of (b). The present invention provides methods and compositions treating or preventing cancer and for sensitizing cancer cells to radiation or a chemotherapeutic agent, which comprises administering i) an anti-p185her2/neu antibody, an anti-EGFR antibody or an erbB kinase inhibitor and interferon-gamma (IFNγ); or ii) a fusion protein of the invention.